Biotheus Has Entered Into An Exclusive License And Collaboration Agreement Under Which BioNTech Will Develop, Manufacture And Commercialize PM8002 Globally Ex-Greater China, Whereas Biotheus Retains The Rights To PM8002 In Greater China
Portfolio Pulse from Benzinga Newsdesk
Biotheus has signed an exclusive license and collaboration agreement with BioNTech for the global development, manufacturing, and commercialization of PM8002, excluding Greater China. PM8002 is currently in Phase 2 studies in China for the treatment of advanced solid tumors.
November 06, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioNTech's partnership with Biotheus for the global development and commercialization of PM8002 could potentially expand its product portfolio and revenue streams.
The partnership with Biotheus allows BioNTech to develop, manufacture, and commercialize PM8002 globally, excluding Greater China. This could potentially expand BioNTech's product portfolio and open new revenue streams if PM8002 proves to be effective and safe in treating advanced solid tumors.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100